Johnson & Johnson reports Q3 2025 results; raises 2025 sales outlook

• 2025 Third-Quarter reported sales growth of 6.8% to $24.0 Billion with operational growth of 5.4%* and adjusted operational growth of 4.4%* • 2025 Third-Quarter reflects earnings per share (EPS) of $2.12 and adjusted EPS of $2.80 • Significant innovation including approvals of INLEXZO for high-risk non-muscle invasive bladder cancer and TREMFYA subcutaneous in ulcerative colitis, submission of icotrokinra for plaque psoriasis, landmark data for RYBREVANT plus LAZCLUZE overall survival in non-small cell lung cancer, and DanGer Shock long-term survival benefit of Impella Heart Pump • Company increases full year estimated reported sales5 guidance to $93.7B or 5.7% at the midpoint; reaffirms full year adjusted EPS4 guidance of $10.85 at the midpoint, absorbing higher tax costsWeiter zum vollständigen Artikel bei Johnson & Johnson Weiter zum vollständigen Artikel bei Johnson & Johnson